Plain-English translation of NCT05443087 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing five different targeted cancer medications — Regorafenib, Everolimus, Sunitinib, Cabozantinib, and Encorafenib-cetuximab — that are already approved and used to treat advanced digestive cancers. Researchers want to understand how much of each medication builds up in your bloodstream and whether that information can help doctors give you the best dose for your specific cancer. By measuring medication levels in blood samples, doctors hope to improve treatment outcomes in the future.
Every patient's body handles medication differently, and getting the right dose is crucial for cancer treatment to work well and cause fewer side effects. Right now, doctors use standard doses for everyone, but this medication may work better or safer at different levels depending on the individual. This study aims to gather information about blood levels so doctors can eventually personalize doses for each patient.
You likely qualify if…
You likely don't qualify if…
You will receive one of the five targeted cancer medications as your standard treatment according to your doctor's plan and medical guidelines. During your treatment, you'll have blood samples taken at a few key times: before you start the medication, one month after starting, two months after starting, if you have any concerning side effects, and if your cancer progresses. Each blood draw involves just one or two small tubes and takes only a few minutes. You'll continue your normal cancer treatment and follow-up visits with your medical team throughout the study.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
France